Emami Limited has informed the Exchange regarding a press release dated May 21, 2026, titled "Emami Reports Q4FY26 Results; Core Domestic Portfolio Remains Resilient Amid External Headwinds".
EMAMILTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Emami reported Q4FY26 consolidated revenues of ₹925 crore, down 4% YoY, impacted by an unfavorable summer season and geopolitical disruptions in West Asia. Despite this, the non-summer domestic portfolio delivered healthy 11% growth, demonstrating underlying business resilience. EBITDA declined 15% to ₹187 crore due to increased A&P investments (+12%), though gross margins expanded by 250 bps to 68.4%. PAT stood at ₹143 crore, down 11.7%. For FY26, revenues were ₹3,780 crore, EBITDA ₹964 crore, and PAT ₹775 crore. The company made strategic investments, including making Axiom Ayurveda (AloFrut) a subsidiary and acquiring a majority stake in IncNut (Vedix, SkinKraft) to strengthen its presence in wellness and personalised beauty segments.
The quarter showed temporary headwinds impacting near-term performance, but strong margin expansion and portfolio diversification indicate resilience. The company remains debt-free with net cash of ₹883 crore, supporting future growth investments and shareholder returns (51% dividend payout ratio).